ARVD/C Dysfunction in Human Stem Cell-Derived Cardiac Tissue

人类干细胞来源的心脏组织中的 ARVD/C 功能障碍

• 批准号: 9106007
• 负责人: LESLIE TUNG
• 金额: $ 40.5万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-04-01 至 2020-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9106007
• 关键词: 3-Dimensional; Action Potentials; Acute; Adipocytes; Adrenergic Agents; Affect; Arrhythmia; Arrhythmogenic Right Ventricular Dysplasia; Athletic; Behavior; Biochemical; Biological Models; Biopsy; Blood; CRISPR/Cas technology; Cardiac; Cardiac Myocytes; Cardiomyopathies; Cell Line; Cell model; Cells; Congenital cardiomyopathy; Counseling; Coupling; Cues; D Cells; Data; Desmosomes; Development; Disease; Disease Management; Disease Pathway; Disease Progression; Electrophysiology (science); Engineering; Exercise; Extracellular Matrix; Fibroblasts; Fibrosis; Functional disorder; Gap Junctions; Generations; Genes; Genetic; Goals; Growth; Heart; Heart Diseases; Heart failure; Hereditary Disease; Histology; Human; Human Genetics; Incidence; Infiltration; Laboratories; Lead; Left ventricular structure; Light; Lipids; Measurement; Mechanics; Modeling; Mutation; Myocardium; Outcomes Research; Pathogenesis; Patients; Phase; Predisposition; Process; Proteins; RNA; Right ventricular structure; Risk; Signal Transduction; Skin; Slice; Sodium; Sodium Channel; Source; Specificity; Staging; Strenuous Exercise; Structural defect; Sudden Death; Syndrome; Testing; Tissue Model; Tissues; Training; Ventricular Arrhythmia; Work; biophysical properties; comparison group; disease phenotype; experience; heart cell; human stem cells; improved; induced pluripotent stem cell; insight; monolayer; new therapeutic target; non-genetic; novel therapeutics; proband; public health relevance; scaffold; simulation; success; sudden cardiac death; therapy design; tissue support frame; tool

 DESCRIPTION (provided by applicant): Advances in the use of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) have dramatically advanced the study of heritable human genetic cardiac diseases. While these advances will eventually lead to new treatment options and improved patient counseling, these cellular model systems also permit mechanistic insights and provide a platform for modeling human cardiac tissues. The latter is critically important as patients with cardiomyopathies (genetic and non-genetic forms) or heart failure often experience arrhythmias that can result in sudden death. To study the predisposition of genetic disease syndromes to cause arrhythmias in cardiac tissue, iPSC-CMs will be cultivated in engineered heart slices (EHS), developed by our team that recapitulate a natural 3D microenvironment and enable electromechanical interactions among cells and the extracellular matrix. Our EHS support the growth of engrafted iPSC-CMs; provide important topological, biochemical, and mechanical signals to the cells; manifest functional tissue behavior, including coordinated electrophysiological and contractile activity; and can sustain cardiac arrhythmias in a quantifiable manner. In this project, we propose to use EHS to investigate mechanisms underlying the manifestation and progression of arrhythmias that promote sudden death. As a genetic tool for modeling arrhythmias, we will study iPSCs generated from probands of arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC) that affect proteins of the cardiac desmosome. In patients, this disease is highly pro-arrhythmic and can lead to sudden cardiac death in young athletes. Hence, the goal of this project is to investigate how structural defects promote arrhythmias in EHS. Specifically we will determine if 1) mutations of desmosomal proteins operate in the early concealed phase of AC to impair intercellular mechanical coupling, resulting in abnormal electrical coupling, slowing of electrical conduction, and reentrant arrhythmia, and 2) secondary alterations in sodium channel function also result in slowing of electrical conduction and arrhythmia. The project involves three complementary and related Aims. Aim 1 will examine the importance of syncytial interactions and tissue microenvironment on the expression and progression of the disease phenotype in ARVC iPSC-CMs. Aim 2 will develop models of simulated exercise to determine increased risk of arrhythmia in EHS models of ARVC. Aim 3 will investigate the instructive cues of different native, extracellular matrices on cellular remodeling and tissue- level arrhythmia in EHS models of ARVC. The outcome of this research will shed light on mechanisms of arrhythmia and sudden cardiac death associated with abnormalities of mechanical junctions that operate not only in ARVC but also in other more common forms of cardiomyopathies. Our study on tissue microenvironment and disease progression in the cardiomyocyte represents a critical step towards the identification of primary and ancillary pro-arrhythmic disease pathways that may prove invaluable to the development of new therapies designed to treat heritable cardiac diseases.

 描述(由申请人提供)：诱导多能干细胞来源的心肌细胞(IPSC-CM)的应用进展极大地推动了可遗传人类遗传性心脏病的研究。虽然这些进展最终将带来新的治疗选择和改进的患者咨询，但这些细胞模型系统也允许进行机械性见解，并为模拟人类心脏组织提供了一个平台。后者是至关重要的，因为患有心肌病(遗传和非遗传形式)或心力衰竭的患者经常经历可能导致猝死的心律失常。为了研究遗传病综合征导致心脏组织心律失常的易感性，我们将在我们团队开发的工程心脏切片(EHS)中培养IPSC-CMS，这种切片概括了自然的3D微环境，并使细胞和细胞外基质之间能够进行机电相互作用。我们的EHS支持植入的IPSC-CMS的生长；为细胞提供重要的拓扑、生化和机械信号；显示功能组织行为，包括协调的电生理和收缩活动；并能够以可量化的方式维持心律失常。在这个项目中，我们建议使用EHS来研究促进猝死的心律失常的表现和进展的潜在机制。作为建模心律失常的遗传学工具，我们将研究致心律失常性右室发育不良/心肌病(ARVC)先证者产生的影响心脏桥粒蛋白的IPSCs。在患者中，这种疾病高度有利于心律失常，并可能导致年轻运动员的心脏性猝死。因此，本项目的目标是研究结构缺陷如何促进EHS中的心律失常。具体地说，我们将确定1)桥粒蛋白突变是否在AC的早期隐匿期起作用，损害细胞间的机械耦合，导致异常的电耦合、电传导减慢和折返性心律失常，以及2)钠通道功能的继发性改变是否也导致电传导减慢和心律失常。该项目涉及三个相辅相成和相互关联的目标。目的1研究合胞相互作用和组织微环境对ARVC IPSC-CMS疾病表型表达和进展的重要性。目的2将开发模拟运动模型，以确定ARVC EHS模型中心律失常风险的增加。目的3探讨不同天然细胞外基质对ARVC EHS模型细胞重构和组织水平心律失常的影响。这项研究的结果将阐明心律失常和心源性猝死的机制，这些机制与机械连接异常有关，不仅在ARVC中操作，而且在其他更常见的心肌病中也是如此。我们对心肌细胞中组织微环境和疾病进展的研究是朝着识别原始和辅助的前心律失常疾病途径迈出的关键一步，这可能被证明对设计用于治疗遗传性心脏病的新疗法的开发具有重要价值。